Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SAN FRANCISCO, Nov. 30, 2017 -- Following the company's release of its latest financial report, three analysts weighed in on the results.
Included in this article is: Viveve Medical Inc. (NASDAQ:VIVE)
In a Nov. 8, 2017, press release, Viveve Medical Inc., a women's health and wellness company, announced record Q3/17 sales of $4.1 million," a 120% year-over-year (YOY) increase. "These results demonstrate continued strong demand for our innovative technology and the Geneveve treatment globally, particularly in North America, our largest commercial market," said Patricia Scheller, the corporation's CEO and director.
Revenue derived from the sale of 60 systems, 47 in North America, and 2,724 treatment tips. "The increasing demand we have seen since launching the Viveve System in Q3/15 reinforces the size of the worldwide opportunity and sets the stage for continuing global adoption through the remainder of the year and into 2018," Scheller concluded.
Viveve's Q3/17 global sales led to greater gross profit of $2 million, or 49% of revenue. This compares to that of Q3/16, which was $691,000, or 37% of revenue.
Continue reading this article: Analysts Say Medical Device Firm Sees Record Quarterly Revenue Growth, 120% YOY
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURES:
The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Viveve Medical Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
Please see the end of the article for the complete disclosures: Analysts Say Medical Device Firm Sees Record Quarterly Revenue Growth, 120% YOY
Contact Information: Carrie Beal Amaro- Publisher ([email protected])
